Oklahoma 2024 Regular Session

Oklahoma Senate Bill SB232 Latest Draft

Bill / Engrossed Version Filed 04/29/2024

                             
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 1  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
ENGROSSED HOUSE AMENDME NT 
 TO 
ENGROSSED SENATE BILL NO . 232 By: Garvin of the Senate 
 
  and 
 
  McEntire of the House 
 
 
 
 
 
[ pharmacy - technicians - ratio - effective date ] 
 
 
 
NOTE: Emergency failed 
 
AUTHORS:  Remove Senator Garvin as principal Senate a uthor and 
substitute with Senator Seifried 
 
Add as coauthor Senator Garvin 
 
 
AMENDMENT NO. 1.  Strike the stricken title, enacting clause, and 
entire bill and insert: 
 
 
 
 
"An Act relating to the practice of pharmacy; 
allowing pharmacist to test or screen for and 
initiate drug therapy for minor, nonchronic health 
conditions; specifying allowed tests; allowing 
pharmacist to dispense certain produ cts under certain 
protocol; directing adoption of rules; amending 59 
O.S. 2021, Section 353.1, as amended by Section 6, 
Chapter 288, O.S.L. 2022 (59 O.S. Supp. 2023, Section 
353.1), which relates to definitions used in the 
Oklahoma Pharmacy Act; modifying and adding 
definitions; amending 59 O.S. 2021, Section 353.18A, 
which relates to pharmacy technicians; establishing 
certain pharmacy rat io; updating statutory lan guage 
and references; and providing for codification. 
 
 
   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 2  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
BE IT ENACTED BY THE PEO PLE OF THE STATE OF OKLAHOMA: 
SECTION 1.     NEW LAW    A new section of law to be codified 
in the Oklahoma Statutes as Section 353.31 of Title 59, unless there 
is created a duplication i n numbering, reads as follows: 
A.  A pharmacist may test or screen for and initiate drug 
therapy for minor, nonchronic health conditions as defined in 
Section 353.1 of Title 59 of the Oklahoma Statutes. 
B.  To test for minor, nonchronic he alth conditions under this 
section, the pharmacist may use any test that may guide clinical 
decision-making and that is: 
1.  Approved by, cleared by, or authorized under an emergency 
use authorization by the United States Food and Drug Administration; 
and 
2.  Waived under the federa l Clinical Laboratory Improvement 
Amendments of 1988 (CLIA) or deemed to be CLIA-waived for use in 
patient care settings operating under a CLIA certificate. 
C.  A pharmacist may dispense self-administered hormonal 
contraceptives under the protocol es tablished pursuant to subsection 
E of this section, regardless of whether the patient has obtained a 
prescription. 
D.  A pharmacist may not test or screen for streptococcus and 
initiate drug therapy for streptococcus to individuals under six (6) 
years of age.   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 3  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
E. The State Board of Pharmacy shall adopt rules establishing a 
protocol for dispensing self-administered hormonal contraceptives by 
January 1, 2025. 
SECTION 2.     AMENDATORY   59 O.S. 2021, Section 353.1, as 
amended by Section 6 , Chapter 288, O.S.L. 2022 (59 O.S. Supp. 2023, 
Section 353.1), is amended to read as follows: 
Section 353.1 For the purposes of the Oklahoma Pharmacy Act: 
1.  “Accredited program” means those seminars, classes, 
meetings, work projects, and oth er educational courses approved by 
the State Board of Pharmacy for purposes of continuing professional 
education; 
2.  “Act” means the Oklahoma Pharmacy Act; 
3.  “Administer” means the direct application of a drug, whether 
by injection, inhalation, ingestion or any other means, to the body 
of a patient; 
4.  “Assistant pharmacist” means any person presently licensed 
as an assistant pharmacist in the State of Oklahom a this state by 
the Board pursuant to Section 353.10 of this title and for the 
purposes of the Okla homa Pharmacy Act shall be considered the same 
as a pharmacist, except where otherwise specified; 
5.  “Board” or “State Board” means the State Board of Pharmacy; 
6.  “Certify” or “certification of a prescription” means the 
review of a filled prescription b y a licensed pharmacist or a 
licensed practitioner with dispensing authority to confirm that the   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 4  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
medication, labeling and packaging of the filled prescription are 
accurate and meet all requirements prescribed by state and federal 
law.  For the purposes of this paragraph, “licensed practitioner” 
shall not include optometrists with dispensing authority; 
7.  “Chemical” means any medicinal substance, whether simple or 
compound or obtained through the process of the science and art of 
chemistry, whether of organ ic or inorganic origin; 
8.  “Compounding” means the combining, admixing, mixing, 
diluting, pooling, reconstituting or otherwise altering of a drug or 
bulk drug substance to create a drug.  Compounding includes the 
preparation of drugs or devices in anticip ation of prescription drug 
orders based on routine, regularly observed prescribing patterns; 
9.  “Continuing professional education” means professional, 
pharmaceutical education in the general areas of the socioeconomic 
and legal aspects of health care; th e properties and actions of 
drugs and dosage forms; and the etiology, characteristics and 
therapeutics of the diseased state; 
10.  “Dangerous drug”, “legend drug”, “prescription drug” or “Rx 
Only” means a drug: 
a. for human use subject to 21 U.S.C. , Section 353(b)(1), 
or 
b. is labeled “Prescription Only”, or labeled with the 
following statement:  “Caution:  Federal law restricts   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 5  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
this drug except for to use by or on the order of a 
licensed veterinarian.”; 
11.  “Director” means the Executive Director of the State Boar d 
of Pharmacy unless context clearly indi cates otherwise; 
12.  “Dispense” or “dispensing” means the interpretation, 
evaluation, and implementation of a prescription drug order 
including the preparation and delivery of a drug or device to a 
patient or a patient’s agent in a suitable container appr opriately 
labeled for subsequent administration to, or use by, a patient.  
Dispense includes sell, distribute, leave with, give away, dispose 
of, deliver or supply; 
13.  “Dispenser” means a retail pharmacy, hospital pharmacy, a 
group of chain pharmacies un der common ownership and control that do 
not act as a wholesale distributor, or any other person authorized 
by law to dispense or administer prescription drugs, and the 
affiliated warehouses or distributions of such entities under common 
ownership and control that do not act as a wholesale distributor.  
For the purposes of this paragraph, “dispenser” dispenser does not 
mean a person who dispenses only products to be used in animals in 
accordance with 21 U.S.C. , Section 360b(a)(5); 
14.  “Distribute” or “distribution” means the sale, purchase, 
trade, delivery, handling, storage, or receipt of a product, and 
does not include the dispensing of a product pursuant to a 
prescription executed in accordance with 21 U.S.C. , Section   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 6  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
353(b)(1) or the dispensing of a pr oduct approved under 21 U.S.C., 
Section 360b(b); provided, taking actual physical possession of a 
product or title shall not be required; 
15.  “Doctor of Pharmacy” means a person licensed by the Board 
to engage in the practice of pharmacy.  The terms “pharmacist”, 
“D.Ph.”, and “Doctor of Pharmacy” shall be interchangeable and s hall 
have the same meaning wherever they appear in the Oklahoma Statutes 
and the rules promulgated by the Board; 
16.  “Drug outlet” means all manufacturers, repackagers, 
outsourcing faciliti es, wholesale distributors, third-party 
logistics providers, pharm acies, and all other facilities which are 
engaged in dispensing, delivery, distribution or storage of 
dangerous drugs; 
17.  “Drugs” means all medicinal substances and preparations 
recognized by the United States Pharmacopoeia Pharmacopeia and 
National Formulary, or any revision thereof, and all substances and 
preparations intended for external and/or internal use in the cure, 
diagnosis, mitigation, treatment or prevention of disease in humans 
or animals and all substances and preparations, other than food, 
intended to affect the structure or any function of the body of a 
human or animals; 
18.  “Drug sample” means a unit of a prescription drug packaged 
under the authority and responsibility of th e manufacturer that is   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 7  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
not intended to be sold and is intended to promote the sale of the 
drug; 
19. “Durable medical equipment” has the same meaning as 
provided by Section 2 375.2 of this act title; 
20. “Filled prescription” means a packaged pres cription 
medication to which a label has been affixed which contains such 
information as is required by the Oklahoma Pharmacy Act; 
21.  “Hospital” means any institution licensed as a hospital by 
this state for the care and treatment of patients, or a pharm acy 
operated by the Oklahoma Department of Veterans Affairs; 
22.  “Licensed practitioner” means an allopathic physician, 
osteopathic physician, podiatric physician, dentist, veterinarian or 
optometrist licensed to practice and authorized to prescribe 
dangerous drugs within the scope of practice of such practitioner; 
23.  “Manufacturer” or “virtual manufacturer” means with respect 
to a product: 
a. a person that holds an application approved under 21 
U.S.C., Section 355 or a license issued under 42 
U.S.C., Section 262 for such product, or if such 
product is not the subject of an approved application 
or license, the person who manufactured the product, 
b. a co-licensed partner of the person described in 
subparagraph a of this paragraph that obtains the   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 8  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
product directly from a person described in this 
subparagraph or subparagraph a of this paragraph, 
c. an affiliate of a person described in su bparagraph a 
or b of this paragraph who receives the product 
directly from a person described in this subparagraph 
or in subparagraph a or b of this paragraph, or 
d. a person who contracts with another to manufacture a 
product; 
24.  “Manufacturing” means the production, preparation, 
propagation, compounding, conversion or processing of a device or a 
drug, either directly or indirectly by extraction from substances of 
natural origin or independently by means of chemical or biological 
synthesis and includes any packaging or repackaging of the 
substances or labeling or relabeling of its container, and the 
promotion and marketing of such drugs or devices.  The term 
“manufacturing” manufacturing also includes the preparation and 
promotion of commercially avail able products from bulk compounds for 
resale by licensed pharmacies, licensed practitioners or other 
persons; 
25.  “Medical gas” means those gases including those in liquid 
state upon which the manufacturer or distributor has placed one of 
several cautions, such as “Rx Only”, in compliance with federal law; 
26.  “Medical gas order” means an order for medical gas issued 
by a licensed prescriber;   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 9  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
27.  “Medical gas distributor” means a person licensed to 
distribute, transfer, wholesale, deliver or sell medical gases on 
drug orders to suppliers or other entities licensed to use, 
administer or distribute medical gas and may also include a patient 
or ultimate user; 
28.  “Medical gas supplier” means a person who disp enses medical 
gases on drug orders only to a pati ent or ultimate user; 
29.  “Medicine” means any drug or combination of drugs which has 
the property of curing, preventing, treating, diagnosing or 
mitigating diseases, or which is used for that purpose; 
30.  “Minor, nonchronic health condition” means a typically 
short-term health condition that is generally managed with 
noncontrolled drug therapies, minimal treatment, or self-care, and 
is limited to the following: 
a. influenzas, 
b. streptococcus, 
c. SARS-CoV-2, 
d. lice, and 
e. other emerging and existing pub lic health threats 
identified by the State Department of Health if 
permitted by an order, rule, or regulation; 
31.  “Nonprescription drugs” means medicines or drugs which are 
sold without a prescription and which are prepackaged for use by the 
consumer and labeled in accordance with the requirements of the   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 10  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
statutes and regulations of this state and the federal government.  
Such items shall also include medical a nd dental supplies and 
bottled or nonbulk chemicals which are sold or offered for sale to 
the general public if such articles or preparations meet the 
requirements of the Federal Food, Drug and Cosmetic Act, 21 
U.S.C.A., Section 321 et seq.; 
31. 32.  “Outsourcing facility” including “virtual outsourcing 
facility” means a facility at one geographic location or address 
that: 
a. is engaged in the compounding of sterile drugs, 
b. has elected to register as an outsourcing facility, 
and 
c. complies with all requi rements of 21 U.S.C., Section 
353b; 
32. 33.  “Package” means the smallest individual saleable unit 
of product for distribution by a manufacturer or repackager that is 
intended by the manufacturer for ultimate sale to the dispenser of 
such product.  For the purposes of this paragraph, “individual 
saleable unit” means the smallest container of a product introduced 
into commerce by the manufacturer or repackager that is intended by 
the manufacturer or repackager for individual sale to a dispenser; 
33. 34.  “Person” means an individual, partnership, limited 
liability company, corporation or association, unless the context 
otherwise requires;   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 11  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
34. 35.  “Pharmacist-in-charge” or “PIC” means the pharmacist 
licensed in this state responsible for the management control of a 
pharmacy and all other aspects of the practice of pharmacy in a 
licensed pharmacy as defined by Section 353.18 of this title; 
35. 36.  “Pharmacy” means a place regularly licensed by the 
State Board of Pharmacy in which prescriptions, drugs, medicines, 
chemicals and poisons are compounded or dispensed or such place 
where pharmacists practice the profession of pharmacy, or a pharmacy 
operated by the Oklahoma Department of Veterans Affairs; 
36. 37.  “Pharmacy technician”, “technician”, “Rx tech”, or 
“tech” means a person issued a Technician permit by the State Board 
of Pharmacy to assist the pharmacist and perform nonjudgmental, 
technical, manipulative, non-discretionary functions in the 
prescription department under the immediate and direct supervision 
of a pharmacist; 
37. 38.  “Poison” means any substance which when introduced into 
the body, either directly or by absorption, produces violent, morbid 
or fatal changes, or which destroys living tissue with which such 
substance comes into contact; 
38. 39.  “Practice of pharmacy” means: 
a. the interpretation and evaluation of prescription 
orders, 
b. the compounding, dispensing, administering and 
labeling of drugs and devices, except labeling by a   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 12  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
manufacturer, repackager or distributor of 
nonprescription drugs and commercially packaged legend 
drugs and devices, 
c. the participation in drug selection and drug 
utilization reviews, 
d. the proper and safe storage of drugs and devices and 
the maintenance of proper records thereof, 
e. the responsibility for advising by counseling and 
providing information, where professionally necessary 
or where regulated, of therapeutic values, content, 
hazards and use of drugs and devices, 
f. the offering or performing of those acts, services, 
operations or transactions necessary in the conduct, 
operation, management and control of a pharmacy, or 
g. the ordering, performing, and interpreting of tests 
for minor, nonchronic health conditions that meet the 
requirements of Section 1 of this act and the 
initiation of drug therapy for minor, nonchronic 
health conditions, 
h. the dispensing of se lf-administered hormonal 
contraceptives as provided by Section 1 of this act, 
or 
i. the provision of those acts or services that are 
necessary to provide pharmaceutical care;   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 13  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
39. 40.  “Preparation” means an article which may or may not 
contain sterile produc ts compounded in a licensed pharmacy pursuant 
to the order of a licensed prescriber; 
40. 41.  “Prescriber” means a person licensed in this state who 
is authorized to prescribe dangerous drugs within the scope of 
practice of the person’s profession; 
41. 42.  “Prescription” means and includes any order for drug or 
medical supplies written or signed, or transmitted by word of mouth, 
telephone or other means of communication: 
a. by a licensed prescriber, 
b. under the supervision of an Oklahoma licensed 
practitioner, an Oklahoma licensed advanced practice 
registered nurse Advanced Practice Registered Nurse or 
an Oklahoma licensed physician assistant, or 
c. by an Oklahoma licensed wholesaler or distributor as 
authorized in Section 353.29.1 of this title; 
42. 43.  “Product” means a prescription drug in a finished 
dosage form for administration to a patient without substantial 
further manufacturing, such as capsules, tablets, and lyophilized 
products before reconstitution. “Product” Product does not include 
blood components intended for transfusion, radioactive drugs or 
biologics and medical gas; 
43. 44.  “Repackager”, including “virtual repackager”, means a 
person who owns or operates an establishment that repacks and   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 14  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
relabels a product or package for further sale or distribution 
without further transaction; 
44. 45.  “Sterile drug” means a drug that is intended for 
parenteral administration, an ophthalmic or oral inhalation drug in 
aqueous format, or a drug that is required to be sterile under state 
and federal law; 
45. 46.  “Supervising physician” means an individual holding a 
current license to practice as a physician from the State Board of 
Medical Licensure and Supervision, pursuant to the provisions of the 
Oklahoma Allopathic Medical and Surgical Licensure and Supervision 
Act, or the State Board of Osteopathic Examiners, pursuant to the 
provisions of the Oklahoma Osteopathic Medicine Act, who supervises 
an advanced practice registered nurse Advanced Practice Registered 
Nurse as defined in Section 567.3a of this title, and who is not in 
training as an intern, resident, or fellow.  To be eligible to 
supervise an advanced practice registered nurse Advanced Practice 
Registered Nurse, such physician shall remain in compliance with the 
rules promulgated by the State Boar d of Medical Licensure and 
Supervision or the State Board of Osteopathic Examiners; 
46. 47.  “Supportive personnel” means technicians and auxiliary 
supportive persons who are regularly paid employees of a pharmacy 
who work and perform tasks in the pharmacy as authorized by Section 
353.18A of this title;   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 15  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
47. 48.  “Third-party logistics provider” including “virtual 
third-party logistics provider” means an entity that provides or 
coordinates warehousing, or other logistics services of a product in 
interstate commerce on behalf of a manufacturer, wholesale 
distributor, or dispenser of a product but does not take ownership 
of the product, nor have responsibility to direct the sale or 
disposition of the product.  For the purposes of this paragraph, 
“third-party logistics provider” third-party logistics provider does 
not include shippers and the United States Postal Service; 
48. 49.  “Wholesale distributor” including “virtual wholesale 
distributor” means a person other than a manufacturer, a 
manufacturer’s co-licensed partner, a third-party logistics 
provider, or repackager engaged in wholesale distribution as defined 
by 21 U.S.C., Section 353(e)(4) as amended by the Drug Supply Chain 
Security Act; 
49. 50.  “County jail” means a facility operated by a county for 
the physical detention and correction of persons charged with, or 
convicted of, criminal offenses or ordinance violations or persons 
found guilty of civil or criminal contempt; 
50. 51.  “State correctional facility” means a facility or 
institution that houses a p risoner population under the jurisdiction 
of the Department of Corrections;   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 16  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
51. 52.  “Unit dose package” means a package that contains a 
single dose drug with the name, strength, control number, and 
expiration date of that drug on the label; and 
52. 53.  “Unit of issue package” means a package that provides 
multiple doses of the same drug, but each drug is individually 
separated and includes the name, lot number, and expirat ion date. 
SECTION 3.     AMENDATORY     59 O. S. 2021, Section 353.18A, is 
amended to read as follows: 
Section 353.18A A.  Supportive personnel may perform certain 
tasks in the practice of pharma cy if such personnel perform the 
tasks in compliance with rules pro mulgated by the State Board of 
Pharmacy. 
B.  1.  No person shall serve as a pharmacy technician w ithout 
first procuring a permit from the Board. 
2.  An application for an initial or renewal pharmacy technician 
permit issued pursuant to the provisions of th is subsection shall be 
submitted to the Board and provide any other information deemed 
relevant by the Board. 
3.  An application for an initial or renewal permit shall be 
accompanied by a permit fee not to exceed Seventy Five Seventy-five 
Dollars ($75.00) for each period of one (1) year.  A permit issued 
pursuant to this subsection shall be valid for a period to be 
determined by the Board.   
 
ENGR. H. A. to ENGR. S. B. NO. 232 	Page 17  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
4.  Every permitted pharmacy technician who fails to complete a 
renewal form and remit the requi red renewal fee to the Board by the 
fifteenth day after the expiration of the permit shall pay a late 
fee to be fixed by the Board. 
5.  A pharmacy technician permit shall be cancelled canceled 
thirty (30) days after expiration. 
6.  A person may obtain rein statement of a cancelled canceled 
pharmacy technician permit by making application, paying a 
reinstatement fee, and sati sfactorily completing other requirements 
set by the Board. 
C.  A licensed pharmacy s hall maintain a pharmacy technician-to-
pharmacist ratio of not more than three pharmacy technicians for 
every one licensed pharmacist." 
Passed the House of Representatives the 25th day of April, 2024. 
 
 
 
 
  
Presiding Officer of the House of 
 	Representatives 
 
 
Passed the Senate the ____ day of _______ ___, 2024. 
 
 
 
 
  
Presiding Officer of the Senate   
 
ENGR. S. B. NO. 232 	Page 1  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
ENGROSSED SENATE 
BILL NO. 232 	By: Garvin of the Senate 
 
  and 
 
  McEntire of the House 
 
 
 
 
[ pharmacy - technicians - ratio - effective date ] 
 
 
 
 
 
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: 
SECTION 4.     AMENDATORY     59 O. S. 2021, Section 353.18A, is 
amended to read as follows: 
Section 353.18A.  A.  Supportive personnel may perform certain 
tasks in the practice of pharmacy if such personnel perform the 
tasks in compliance with rules promulgated by the State Board of 
Pharmacy. 
B.  1.  No person shall serve as a pharmacy technician without 
first procuring a permit from the Board. 
2.  An application for an initial or renewal pharmacy technician 
permit issued pursuant to the provisions of this subsection shall be 
submitted to the Board and provide any other information deemed 
relevant by the Board. 
3.  An application for an initial or renewal permit shall be 
accompanied by a permit fee not to exceed Seventy Five Seventy-five 
Dollars ($75.00) for each period of one (1) year.  A pe rmit issued   
 
ENGR. S. B. NO. 232 	Page 2  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
pursuant to this subsection shall be valid for a period to be 
determined by the Board. 
4.  Every permitted pharmacy technician who fails to complete a 
renewal form and remit the required renewal fee to the Board by the 
fifteenth day after the e xpiration of the permit shall pay a late 
fee to be fixed by the Board. 
5.  A pharmacy technician permit shall be cancelled canceled 
thirty (30) days after expiration. 
6.  A person may obtain reinstatement of a cancelled canceled 
pharmacy technician permit by making application, paying a 
reinstatement fee, and satisfactorily complet ing other requirements 
set by the Board. 
C.  A licensed pharmacy s hall maintain a pharmacy technician -to-
pharmacist ratio of not more than five pharmacy technicians for 
every one licensed pharmacist. 
SECTION 5.  This act shall become effect ive November 1, 2024.   
 
ENGR. S. B. NO. 232 	Page 3  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
Passed the Senate the 11th day of March, 2024. 
 
 
  
 	Presiding Officer of the Senate 
 
 
Passed the House of Representatives the ____ day of __________, 
2024. 
 
 
  
 	Presiding Officer of the House 
 	of Representatives